Lifeward (NASDAQ:LFWD) Trading Down 2.3% – Should You Sell?

Shares of Lifeward Ltd. (NASDAQ:LFWD) were down 2.3% on Wednesday . The company traded as low as $0.6251 and last traded at $0.6350. Approximately 72,799 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 846,895 shares. The stock had previously closed at $0.65.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LFWD. Weiss Ratings reissued a “sell (e+)” rating on shares of Lifeward in a report on Wednesday, October 8th. HC Wainwright decreased their target price on Lifeward from $13.00 to $4.50 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Lifeward presently has a consensus rating of “Moderate Buy” and an average price target of $6.17.

Lifeward Price Performance

The company has a market capitalization of $11.61 million, a price-to-earnings ratio of -0.21 and a beta of 0.01. The firm’s fifty day moving average price is $0.62 and its 200-day moving average price is $0.70.

Lifeward (NASDAQ:LFWD) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.06). Lifeward had a negative net margin of 121.82% and a negative return on equity of 183.18%. The firm had revenue of $6.20 million for the quarter, compared to analyst estimates of $6.31 million. On average, research analysts predict that Lifeward Ltd. will post -1.78 earnings per share for the current year.

Institutional Trading of Lifeward

An institutional investor recently raised its position in Lifeward stock. Citadel Advisors LLC increased its position in Lifeward Ltd. (NASDAQ:LFWD) by 1,271.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 214,006 shares of the company’s stock after buying an additional 198,406 shares during the quarter. Citadel Advisors LLC owned 1.36% of Lifeward worth $152,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 26.76% of the company’s stock.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.